Literature DB >> 29221227

PET-guided treatment algorithms in oesophageal cancer: the promise of the near future!

Lioe-Fee de Geus-Oei1,2, Marije Slingerland3.   

Abstract

Entities:  

Year:  2017        PMID： 29221227      PMCID： PMC5708382          DOI： 10.21037/jtd.2017.07.115

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; L Xiao; J A Roth; W L Hofstetter; G Walsh; R Komaki; Z Liao; D C Rice; A A Vaporciyan; D M Maru; J H Lee; M S Bhutani; A Eid; J C Yao; A P Phan; A Halpin; A Suzuki; T Taketa; P F Thall; S G Swisher
Journal:  Ann Oncol       Date:  2013-08-23       Impact factor: 32.976

3.  Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Authors:  David H Ilson; Bruce D Minsky; Geoffrey Y Ku; Valerie Rusch; Nabil Rizk; Manish Shah; David P Kelsen; Marinela Capanu; Laura Tang; Jenny Campbell; Manjit Bains
Journal:  Cancer       Date:  2011-10-11       Impact factor: 6.860

4.  Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.

Authors:  Dok Hyun Yoon; Geundoo Jang; Jong Hoon Kim; Yong-Hee Kim; Ji Youn Kim; Hyeong Ryul Kim; Hwoon-Yong Jung; Gin-Hyug Lee; Ho Young Song; Kyung-Ja Cho; Jin-Sook Ryu; Sung-Bae Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

5.  Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

Authors:  Geoffrey Y Ku; Anuja Kriplani; Yelena Y Janjigian; David P Kelsen; Valerie W Rusch; Manjit Bains; Joanne Chou; Marinela Capanu; Abraham J Wu; Karyn A Goodman; David H Ilson
Journal:  Cancer       Date:  2016-05-06       Impact factor: 6.860

6.  18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.

Authors:  Mian Xi; Zhongxing Liao; Wayne L Hofstetter; Ritsuko Komaki; Linus Ho; Steven H Lin
Journal:  J Nucl Med       Date:  2017-05-18       Impact factor: 10.057

7.  Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).

Authors:  Bernd Klaeser; Egbert Nitzsche; Jan C Schuller; Dieter Köberle; Lucas Widmer; Sabine Balmer-Majno; Thomas Hany; Corinne Cescato-Wenger; Peter Brauchli; Michael Zünd; Bernhard C Pestalozzi; Clemens Caspar; Susanne Albrecht; Roger von Moos; Thomas Ruhstaller
Journal:  Onkologie       Date:  2009-11-09

8.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

9.  Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma.

Authors:  Arpit Chhabra; Leonard T Ong; Deborah Kuk; Geoffrey Ku; David Ilson; Yelena Y Janjigian; Abraham Wu; Heiko Schöder; Karyn A Goodman
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640

10.  The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.

Authors:  Peter S N van Rossum; David V Fried; Lifei Zhang; Wayne L Hofstetter; Linus Ho; Gert J Meijer; Brett W Carter; Laurence E Court; Steven H Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-11       Impact factor: 9.236
View more
  2 in total

1.  Prognostic and predictive values of interim 18F-FDG PET during neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis.

Authors:  Sangwon Han; Yong-Il Kim; Sungmin Woo; Tae-Hyung Kim; Jin-Sook Ryu
Journal:  Ann Nucl Med       Date:  2021-01-20       Impact factor: 2.668

2.  Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma.

Authors:  Yimin Li; Frank Hofheinz; Christian Furth; Chen Lili; Wu Hua; Pirus Ghadjar; Sebastian Zschaeck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-21       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.